key: cord-0714041-bfhf739g
authors: Fabian, Ido Didi; Stacey, Andrew W.; Bowman, Richard; Khetan, Vikas; Blum, Sharon; Keren‐Froim, Naama; Staffieri, Sandra; Foster, Allen
title: Retinoblastoma management during the COVID‐19 pandemic: A report by the Global Retinoblastoma Study Group including 194 centers from 94 countries
date: 2020-08-06
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.28584
sha: 1b508c6b36e9102ead78cacdab3e3ca484df8a7c
doc_id: 714041
cord_uid: bfhf739g

nan

). Table S1 shows the COVID-19 data per participating country during the study period, data on travel restrictions, and policy for retinoblastoma patients. In 51 countries (54.3%), there were fewer than 100 COVID-19-positive cases per average day; in 30 countries (31.9%), there were between 100 and 999 new positive cases; and in 9 (9.6%) countries, there were between 1000 and 10 000 new positive cases per day. In terms of deaths, no cases were reported in 23 (24.5%) of the participating countries; in 50 (53.2%) countries, there were 1 to 9 deaths per day on average; and in 17 (18.1%) countries; there were between 10 and 499 deaths per day on average. In Overall, 16 (8.3%) centers reported that retinoblastoma management was disrupted due to personnel being quarantined or sick (i.e., COVID-19 positive), 11 (5.7%) due to personnel being needed elsewhere, 7 (3.6%) due to equipment being needed elsewhere/missing, 40 (20.6%) due to a combination of factors, and 120 (61.9%) reported no disruption. 

We declare no competing interests relevant to the present work. Allen Foster 1 on behalf of the Global Retinoblastoma Study Group

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

WHO Director General's opening remarks at the media briefing on COVID-19

COVID-19: global consequences for oncology

Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. Pediatr Blood Cancer

The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death

Retinoblastoma in the United States: a 40-year incidence and survival analysis

Retinoblastoma: treatment and survival in Great Britain

Global retinoblastoma presentation and analysis by National Income Level

World Health Organization. Coronavirus disease (COVID-19) outbreak

Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis

Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre

Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis

The complete list of authors is shown in the Supporting Information File.

Ido Didi Fabian https://orcid.org/0000-0002-0846-5131